Abstract: Disclosed is a pharmaceutical composition for use in desensitizing hypersensitive dentin or eliminating odontalgia comprising N-methacryloyl aminosalicylic acid as an active ingredient. The composition may further include an unsaturated compound and a polymerization initiator optionally for retaining the desensitizing effect.
Abstract: The hydrated complex of magnesium acetylsalicylate and urea of formula ##STR1## possesses exceptional analgesic and antipyretic properties. It may be crystallized from a solution obtained by reacting acetylsalicylic acid with magnesium carbonate in the presence of urea.
Abstract: Presenile and senile dementia, in particular Alzheimer's disease, can be combated or alleviated by administration of an effective amount of a physiologically acceptable lithium compound and an essential fatty acid or a physiologically acceptable salt thereof.
Abstract: A hydroalcoholic solution with pH 2-3.5 of salicylic acid and an anionic taurate surfactant selected from the group consisting of sodium methyl cocoyl taurate and sodium methyl oleoyl taurate.
Abstract: A combination of verapamil, gallopamil or anipamil and acetylsalicylic acid in a weight ratio of from 10:1 to 2:1 being useful in the treatment of circulatory disorders.
Type:
Grant
Filed:
January 7, 1988
Date of Patent:
January 17, 1989
Assignee:
BASF Aktiengesellschaft
Inventors:
Hans D. Lehmann, Rolf Kretzschmar, Klaus-Juergen Hahn
Abstract: A pharmaceutical composition and process for administering non-steroidal drugs which are protected against injury to the gastrointestinal tract by a combination of certain H.sub.1 and H.sub.2 receptor blockers.
Type:
Grant
Filed:
April 29, 1986
Date of Patent:
July 12, 1988
Assignee:
Bristol-Myers Company
Inventors:
Alison B. Lukacsko, Randy J. Koslo, Joseph J. Piala
Abstract: Derivatives of 3-aminopropane-1,2-diol of the formula ##STR1## in which Ar represents optionally substituted aryl,n represents the number 0 or 1, andalk represents alkylene having 2 to 5 carbon atoms, the nitrogen atom and the oxygen atom, or, if n is zero, the phenyl radical, being separated from one another by at least two carbon atoms, andR.sub.1 and R.sub.2, independently of one another, each represents hydrogen or lower alkyl, or together they represent lower alkylene, oxa-lower alkylene, thia-lower alkylene, aza-lower alkylene or N-lower alkyl-aza-lower alkylene,and salts of such compounds, processes for their manufacture, medicaments containing the new compounds and their use for the treatment of Angina pectoris and cardiac arrhythmia, and as blood pressure-reducing agents, as well as for the treatment of reactive or endogenic states of depression.
Abstract: A preparation for percutaneous administration of nitroglycerine, said preparation comprising nitroglycerine incorporated in a cream base in an amount not less than about 0.05% by weight based on the total weight of the preparation. The composition may also contain other medicaments, the bioavailability of which is enhanced by the nitroglycerine. The action of the preparation against for example angina may be brought about by having an appropriate amount of nitroglycerine or as additional medicament another medicament active against angina. The preparation may contain an hydroxyalkylcellulose which may provide, in combination with a waxy component in the cream, for example a higher aliphatic alcohol, a prolonged release effect. The preparation has advantages particularly as regards bioavailability over prior uniphasic ointments.
Type:
Grant
Filed:
August 14, 1985
Date of Patent:
March 31, 1987
Assignee:
Euroceltique, S.A.
Inventors:
Stewart T. Leslie, Alan Rhodes, Cyril Boroda, Alfred Halpern
Abstract: 13-thiaprostaglandins of Formula I ##STR1## wherein B is --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--,R.sup.1 is phenyl, CH.sub.3, or NH.sub.2,R.sup.2 is H or CH.sub.3, andR.sup.3 is pentyl, hexyl, 1-methylpentyl, or 1,1-dimethylpentylhave valuable pharmacological properties, e.g., as cytoprotective agents.
Type:
Grant
Filed:
November 8, 1984
Date of Patent:
November 11, 1986
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Abstract: Analgesic and anti-inflammatory compositions are provided which comprise a therapeutically effective amount of a first agent selected from the group consisting of D-phenylalanine, DL-phenylalnine, D-leucine, and DL-leucine and synergistically effective amount of a second therapeutic agent selected from the group consisting of aspirin and an aspirin-type non-steroidal anti-inflammatory, anti-pyretic agent.
Type:
Grant
Filed:
October 4, 1984
Date of Patent:
April 1, 1986
Assignee:
Endorfin, Inc.
Inventors:
Seymour Ehrenpreis, Joseph E. Comaty, Reuben C. Balagot
Abstract: A gel preparation for external application by being prepared from diclofenac sodium as the active ingredient, water, lower alkanols and glycols as medium, a carboxyvinyl polymer as gelating agent, a weak basic substances and optionally adding peppermint oil, l-menthol or salicylic acid ester as auxiliary agent.
Abstract: The invention relates to a process for the production of pharmaceutical preparations based on 5-aminosalicylic acid in which the 5-aminosalicylic acid is mixed with physiologically and toxicologically acceptable, basic auxiliaries and/or buffer mixtures, which in a 1% aqueous solution give pH-values in the range from 8 to 12, and the mixture obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories, or in which the 5-aminosalicylic acid is mixed with a concentrated aqueous solution of the above-mentioned basic auxiliaries and/or buffer mixtures, the 5-aminosalicylic acid salt formed is precipitated, separated off from the aqueous solution and dried and the salt obtained is processed in known manner to form tablets, film tablets, dragees, capsules or suppositories.
Abstract: An analgesic aspirin composition in dosage form having acetylsalicylic acid and unreacted glycine in an amount equal to at least approximately 33.3% of the weight of the acetylsalicylic acid for rendering the aspirin nontoxic upon swallowing the aspirin composition, as well as rendering the aspirin sublingually absorbable.
Type:
Grant
Filed:
October 31, 1983
Date of Patent:
September 3, 1985
Assignee:
Dynatech Laboratories, Incorporated
Inventors:
Charles E. Bender, deceased, Audrey L. Bender, executrix
Abstract: Compositions for the relief of pain, muscle spasm and limited mobility associated with acute painful muscoloskeletal conditions are disclosed. Such compositions comprise in combination, a N-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamate and aspirin.
Abstract: Compositions for the relief of pain, muscle spasm and limited mobility associated with acute painful muscoloskeletal conditions are disclosed. Such compositions comprise in combination, a N-monosubstituted-2, 2-dialkyl-1, 3-propanediol dicarbamate, aspirin and codeine.
Abstract: The subject invention relates to analgesic gels which comprise1. from 5 to 15 parts of an analgesic compound;2. from 10 to 40 parts of a nonionic surfactant which forms a gel in water alone at about 15 to 30 percent by weight based upon the weight of the water plus the weight of the nonionic surfactant;3. from 5 to 40 parts of glycerin;4. from 40 to 75 parts of water; and5. optional ingredients (q.v.)said parts based upon 100 parts of the composition and provided that the weight ratio of nonionic surfactant to water is from 5:1 to 3:1.The subject gels are clear, water soluble and are not tacky when applied to the skin.
Abstract: An analgesic capsule containing asprin and APAP. The aspirin is in the form of an enteric coated granule, and the APAP is present in powder form.